TY - JOUR T1 - The Impact of Coronavirus Disease 2019 (COVID-19) on Liver Injury in China: A Systematic Review and Meta-analysis JF - medRxiv DO - 10.1101/2020.05.03.20089557 SP - 2020.05.03.20089557 AU - Xin Zhao AU - Zehua Lei AU - Fengwei Gao AU - Qingyun Xie AU - Kangyi Jang AU - Jianping Wu AU - Jinqiang Fu AU - Bo Du AU - Zhixu Wang Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/08/2020.05.03.20089557.abstract N2 - Background The evidence for the incidence and severity of liver injury in Chinese patients with COVID-19 is still controversial.Aims The purpose of this study was to summarize the incidence of liver injury and the differences between liver injury markers among different patients with COVID-19 in China.Methods Computer searches of PubMed, Embase, CNKI and medRxiv were used to obtain reports on the incidence and markers of liver injury in Chinese patients with COVID-19, from January 1, 2020 to April 10, 2020. (No. CRD42020181350)Results A total of 57 reports from China were included, including 9889 confirmed cases of COVID-19 infection. The results of the meta-analysis showed that among the patients with early COVID-19 infection in China, the incidence of liver injury events was 24.7% (95% CI, 23.4%-26.4%). Liver injury in severe patients was more common than that in non-severe patients, with a risk ratio of 2.07 (95% CI, 1.77 to 2.43). Quantitative analysis showed that the severe the coronavirus infection, the higher the level of AST, ALT, TB, ALP, GGT and the lower the level of ALB. The changing trend of the appeal index was similar in ICU patients and dead patients.Conclusion There is a certain risk of liver injury in Chinese patients with COVID-19, and the risk and degree of liver injury are related to the severity of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialCRD42020181350Funding StatementNo fundingAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data in the manuscript is availableCOVID-19Coronavirus Disease 2019ALTAlanine aminotransferaseASTAspertate aminotransferaseTBTotal bilirubinALPAlkaline phosphataseGGTγ-glutamyl transpeptidaseALBAlbuminCNKIChina National Knowledge Infrastructure ER -